These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 25918297)

  • 1. Evidence-Based Diagnostic Algorithm for Glioma: Analysis of the Results of Pathology Panel Review and Molecular Parameters of EORTC 26951 and 26882 Trials.
    Kros JM; Huizer K; Hernández-Laín A; Marucci G; Michotte A; Pollo B; Rushing EJ; Ribalta T; French P; Jaminé D; Bekka N; Lacombe D; van den Bent MJ; Gorlia T
    J Clin Oncol; 2015 Jun; 33(17):1943-50. PubMed ID: 25918297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.
    Wick W; Meisner C; Hentschel B; Platten M; Schilling A; Wiestler B; Sabel MC; Koeppen S; Ketter R; Weiler M; Tabatabai G; von Deimling A; Gramatzki D; Westphal M; Schackert G; Loeffler M; Simon M; Reifenberger G; Weller M
    Neurology; 2013 Oct; 81(17):1515-22. PubMed ID: 24068788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT promoter methylation in gliomas: use with caution.
    Boots-Sprenger SH; Sijben A; Rijntjes J; Tops BB; Idema AJ; Rivera AL; Bleeker FE; Gijtenbeek AM; Diefes K; Heathcock L; Aldape KD; Jeuken JW; Wesseling P
    Mod Pathol; 2013 Jul; 26(7):922-9. PubMed ID: 23429602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progress in the application of molecular biomarkers in gliomas.
    Wang J; Su HK; Zhao HF; Chen ZP; To SS
    Biochem Biophys Res Commun; 2015 Sep; 465(1):1-4. PubMed ID: 26253473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive biomarkers in adult gliomas: the present and the future.
    Thomas L; Di Stefano AL; Ducray F
    Curr Opin Oncol; 2013 Nov; 25(6):689-94. PubMed ID: 24076583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glioma biology and molecular markers.
    Cohen AL; Colman H
    Cancer Treat Res; 2015; 163():15-30. PubMed ID: 25468223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical impact of molecular biomarkers in gliomas.
    Siegal T
    J Clin Neurosci; 2015 Mar; 22(3):437-44. PubMed ID: 25533211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors.
    Ueki K; Nishikawa R; Nakazato Y; Hirose T; Hirato J; Funada N; Fujimaki T; Hojo S; Kubo O; Ide T; Usui M; Ochiai C; Ito S; Takahashi H; Mukasa A; Asai A; Kirino T
    Clin Cancer Res; 2002 Jan; 8(1):196-201. PubMed ID: 11801559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chromosome 1p/19q status combined with expression of p53 protein improves the diagnostic and prognostic evaluation of oligodendrogliomas.
    Xiong J; Liu Y; Wang Y; Ke RH; Mao Y; Ye ZR
    Chin Med J (Engl); 2010 Dec; 123(24):3566-73. PubMed ID: 22166632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas.
    Li MY; Wang YY; Cai JQ; Zhang CB; Wang KY; Cheng W; Liu YW; Zhang W; Jiang T
    PLoS One; 2015; 10(6):e0130872. PubMed ID: 26115094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytogenetic and molecular genetic study on granular cell glioblastoma: a case report.
    Joo M; Park SH; Chang SH; Kim H; Choi CY; Lee CH; Lee BH; Hwang YJ
    Hum Pathol; 2013 Feb; 44(2):282-8. PubMed ID: 23058249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of genetic targets on primary brain tumor therapy: what's ready for prime time?
    Zalatimo O; Zoccoli CM; Patel A; Weston CL; Glantz M
    Adv Exp Med Biol; 2013; 779():267-89. PubMed ID: 23288644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. WT1 expression increases with malignancy and indicates unfavourable outcome in astrocytoma.
    Rauscher J; Beschorner R; Gierke M; Bisdas S; Braun C; Ebner FH; Schittenhelm J
    J Clin Pathol; 2014 Jul; 67(7):556-61. PubMed ID: 24607494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In Vivo Molecular Profiling of Human Glioma : Cross-Sectional Observational Study Using Dynamic Susceptibility Contrast Magnetic Resonance Perfusion Imaging.
    Hempel JM; Schittenhelm J; Klose U; Bender B; Bier G; Skardelly M; Tabatabai G; Castaneda Vega S; Ernemann U; Brendle C
    Clin Neuroradiol; 2019 Sep; 29(3):479-491. PubMed ID: 29468261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IDH1 mutation of gliomas with long-term survival analysis.
    Myung JK; Cho HJ; Park CK; Kim SK; Phi JH; Park SH
    Oncol Rep; 2012 Nov; 28(5):1639-44. PubMed ID: 22922798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of heterozygosity analysis in malignant gliomas.
    Mizoguchi M; Kuga D; Guan Y; Hata N; Nakamizo A; Yoshimoto K; Sasaki T
    Brain Tumor Pathol; 2011 Jul; 28(3):191-6. PubMed ID: 21629980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients.
    Felsberg J; Rapp M; Loeser S; Fimmers R; Stummer W; Goeppert M; Steiger HJ; Friedensdorf B; Reifenberger G; Sabel MC
    Clin Cancer Res; 2009 Nov; 15(21):6683-93. PubMed ID: 19861461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Updates in prognostic markers for gliomas.
    Aquilanti E; Miller J; Santagata S; Cahill DP; Brastianos PK
    Neuro Oncol; 2018 Nov; 20(suppl_7):vii17-vii26. PubMed ID: 30412261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic stratification of patients with anaplastic gliomas according to genetic profile.
    Dehais C; Laigle-Donadey F; Marie Y; Kujas M; Lejeune J; Benouaich-Amiel A; Pedretti M; Polivka M; Xuan KH; Thillet J; Delattre JY; Sanson M
    Cancer; 2006 Oct; 107(8):1891-7. PubMed ID: 16986124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
    Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
    Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.